Panbela Therapeutics, INC

Panbela Therapeutics reduces annual compensation for its CEO and CFO, effective February 12, 2025.

Panbela Therapeutics approves retention bonuses for key employees, including the CEO and CFO, to incentivize continued employment through potential milestones or December 31, 2025.

Panbela Therapeutics reports an event of default on its convertible notes, potentially leading to increased interest rates and the lender's option to convert debt into equity.

Panbela Therapeutics has finalized a $9.15 million financing agreement with Nant Capital through the issuance of a Senior Convertible Promissory Tranche B Note.

Panbela Therapeutics announced a $12 million strategic financing from Nant Capital, along with progress in its clinical trials and third-quarter 2024 financial results.

Panbela Therapeutics has entered into a note purchase agreement for $12 million in convertible debt financing to support general corporate purposes and repay existing debt.

Panbela Therapeutics reported a net loss of $21.4 million for the nine months ended September 30, 2024, while navigating financial challenges and making progress in its clinical trials.

Panbela Therapeutics reported its Q2 2024 financial results, highlighting increased research and development expenses due to the ASPIRE trial, while also facing significant liquidity challenges and a potential CRO termination.

Panbela Therapeutics reported a net loss of $7.1 million for Q1 2024, alongside ongoing financial and operational challenges including a recent delisting from Nasdaq.

Panbela Therapeutics' 2023 annual report details financial results, clinical trial updates, and strategic developments, including a reverse stock split and a public offering.

Nant Capital, LLC, and its owner Patrick Soon-Shiong, have increased their stake in Panbela Therapeutics through the purchase of an 8% Senior Convertible Note, potentially converting into a significant portion of the company's common stock.

Susan Horvath, CFO of Panbela Therapeutics, received stock options for 25,480 shares on October 1, 2024.

Jennifer K. Simpson, President and CEO of Panbela Therapeutics, Inc., acquired stock options on October 1, 2024.

Panbela Therapeutics has rescheduled its Special Meeting of Stockholders to May 28, 2024, and is seeking approval for a reverse stock split to meet listing requirements.

Panbela Therapeutics issues preferred stock to its Chairman, plans for CBOE listing, and postpones special meeting due to Nasdaq delisting.

Panbela Therapeutics is asking stockholders to approve a reverse stock split to increase its stock price and meet Nasdaq's listing requirements.

Panbela Therapeutics aims to raise capital for clinical development and debt repayment through a public offering to support a Nasdaq relisting effort.

Panbela Therapeutics is undertaking a firm commitment public offering of common stock and warrants, alongside a proposed reverse stock split, to meet listing requirements for the US Equity Listings Tier II of the CBOE.

Panbela Therapeutics is registering the resale of up to 255,600 shares of its common stock by selling securityholders, while facing challenges with Nasdaq listing compliance.

Panbela Therapeutics is undertaking a best efforts public offering to raise up to $27.8 million for the clinical development of its cancer treatment candidates and for general corporate purposes.

Panbela Therapeutics aims to raise capital through a public offering of common stock and warrants to fund the clinical development of its cancer treatment candidates.

Panbela Therapeutics launches a best efforts public offering of common stock and warrants to raise capital and address Nasdaq compliance issues.

Nant Capital, LLC and Patrick Soon-Shiong have acquired the right to convert notes into 86.98% of Panbela Therapeutics, Inc.'s common stock, following a $12 million private placement of senior convertible promissory notes.